# Agile Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/agile-bio

- Industry: Materials
- Headquarters: Suzhou, China
- Website: www.agilebio.com.cn
- Total disclosed funding: $14M
- Latest round: Series C (Feb 12, 2025)
- Investors on record: 10

## About

Founded in 2020 and based in Suzhou, China, Agile Bio is a bioelectronics technology company that focuses on the research and development of medical instruments and magnetic solid-phase materials. In September 2023, the firm raised approximately CNY 100 million in series B funding co-led by new investor Jiarui Investment and returning investor Cowin Capital. Other new investors Golden Malus Fund, Suzhou Industrial Park Science and Technology Innovation Fund, Tiandi Chouqin, and returning investor Oriza Holdings also participated in the round. As of 2023, the company has obtained or applied for more than 60 intellectual property rights including invention patents, utility model patents, and software copyrights. It has passed ISO9001 quality management system certification. 

In February 2025, Agile Bio closed series C funding from new investors BGI Co-WIN Investment Management and Detong Capital, and other investors.

The company's main products include special chromatographic separation and adsorption materials, mSPE fully automatic magnetic bead extraction technology and products, etc. Special chromatographic separation and adsorption materials include organically bonded silica gel, protein limited ingress, core-shell, magnetic solid-phase extraction, and other chromatographic media.

The company’s revenue is generated by providing new materials and automation systems in the fields of biomedicine, clinical testing, food testing, etc.

The company will use the funding for industrial chain layout and dual-brand promotion, and accelerate the construction of a complete drug separation and purification solution and a clinical mass spectrometry pre-treatment automation solution platform.

## Funding rounds

- Series C, Feb 12, 2025 — Detong Capital, BGI Co-WIN Investment Management
- Series B, Sep 1, 2023, $14M — Oriza Holdings, Cowin Capital, Tiandi Chouqin, Golden Malus Fund, Jiarui Investment, Suzhou Industrial Park Science and Technology Innovation Fund
- Series A, Apr 23, 2022 — Oriza Holdings, Cowin Capital, Shangshi Fund, Trinity Innovation Fund

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A, Series B
- Shangshi Fund (https://capitalatlas.ai/funds/shangshi-fund) — Series A
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series A
- Tiandi Chouqin (https://capitalatlas.ai/funds/tiandi-chouqin) — Series B
- Golden Malus Fund — Series B
- Jiarui Investment (https://capitalatlas.ai/funds/jiarui-investment) — Series B
- Suzhou Industrial Park Science and Technology Innovation Fund — Series B
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series C
- BGI Co-WIN Investment Management (https://capitalatlas.ai/funds/bgi-co-win-investment-management) — Series C